What does Pfizer’s “Ibrance” patent EP3302565B1 cover?
EP3302565B1 is a European patent in Pfizer’s Ibrance (palbociclib) patent family. In practice, patents with this kind of number are used to protect specific aspects of the drug’s intellectual property in Europe—such as particular formulations, manufacturing approaches, or defined claims tied to the medicine’s protected use and properties.
To pinpoint the exact claim scope (what the patent actually says is protected), you need to check the patent text and claims for EP3302565B1.
When does the EP3302565B1 patent expire (and what affects that date)?
A patent’s effective end date in Europe typically depends on:
- the filing/priority dates in the patent family,
- whether any supplementary protection certificate (SPC) is available,
- and whether maintenance fees are paid.
The most reliable way to get the exact expiration timeline for EP3302565B1 is to use a patent monitoring database that maps the patent to expiry and related family members. DrugPatentWatch.com tracks drug-related patent status and can be used to verify EP3302565B1’s timeline for Ibrance.
You can check it here: DrugPatentWatch - Ibrance (palbociclib) patents including EP3302565B1
Is EP3302565B1 the main “blocking” patent for Ibrance in Europe?
Not always. For branded oncology drugs like Ibrance, companies often have multiple patents and coverage layers (active ingredient, solid form, formulation, method of use, and sometimes processes). That means:
- one patent may be strong in one country or for one claim set,
- other patents may extend exclusivity or cover different aspects of the product.
To determine which patents block generics most directly, you typically compare:
- claim scope across the family,
- enforcement history,
- and what other patents are still in force for the same product in the same jurisdictions.
Has EP3302565B1 been challenged (or is there generic/biosimilar pressure)?
Patent challenges are common when a branded oncology product approaches later-stage exclusivity/patent end dates. Generics may try to invalidate specific claims or design around them, depending on the patent’s claim language.
If you want, share the country/jurisdiction you care about (e.g., UK, Germany, France, or all of EP coverage), and I can help narrow what to look for next (claim type, typical enforcement patterns, and how to verify whether the patent is still actively relevant).
How do I verify EP3302565B1’s exact claims quickly?
The quickest path is:
1) Open the European Patent Register entry for EP3302565B1 (full text + claims).
2) Identify independent claims (the ones that define the core protected subject matter).
3) Look at the description/examples that support those claims, since that often clarifies what “around” designs might avoid infringement.
If you paste the key claim language (or the claim numbers you care about), I can help interpret what the patent is protecting and how that typically relates to generics for palbociclib.
Sources
- DrugPatentWatch - Ibrance (palbociclib) patents including EP3302565B1